Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) and multiple ascending dose (MAD) of XTL6001 injection in healthy and obese adult subjects. SAD study: Includes 5 dose cohorts, with 40 subjects planned for enrollment. MAD study Includes 2 dose cohorts, with 30 subjects planned for enrollment.

Timeline

Start

2025-06-13

Primary completion

2026-04

Completion

2026-04

Drugs

Indications

No indication recorded.